Autoantibody-mediated platelet clearance

Autoantibody-mediated platelet clearance" is not a single molecule or canonical therapeutic target but rather describes a pathological process central to diseases such as immune thrombocytopenia (ITP). In ITP, patients develop autoantibodies—most commonly against the platelet glycoproteins GPIIb/IIIa and GPIb/IX/V—which bind to platelets. This binding triggers several mechanisms leading to accelerated removal of platelets from circulation: * Opsonization by antibodies leads to phagocytosis by splenic macrophages and dendritic cells. * Complement activation can further mark platelets for destruction. * Autoantibody binding induces apoptosis in platelets through signaling pathways involving Akt activation and phosphatidylserine exposure, which serve as "eat-me" signals" for macrophages. * Desialylation—the removal of sialic acid residues from glycoproteins on the platelet surface—further promotes their recognition and clearance by hepatic macrophages. This desialylation can be triggered directly by certain classes of antiplatelet antibodies independent of Fc-receptor engagement. Therapeutic strategies do not target "autoantibody-mediated platelet clearance" itself but rather aim at reducing antibody production/effects or stimulating new platelet production. These include intravenous immunoglobulin therapy, corticosteroids, rituximab (anti-CD20), splenectomy in refractory cases, and thrombopoietin receptor agonists that stimulate megakaryocytes to produce more platelets despite ongoing destruction. Because this entry refers to a disease mechanism—not a discrete molecular entity—it is not considered an appropriate canonical drug target according to standard pharmacological classification systems.

Other names

Autoantibody-mediated platelet destructionImmune thrombocytopenia (ITP) mechanismAntiplatelet autoantibody-induced clearance

IVIg: Clearance of autoantibodies via FcRn and modulation of Fcγ receptors; Thrombopoietin receptor agonists: Stimulate megakaryocyte proliferation and proplatelet formation; may also inhibit platelet destruction by modulating Fcγ receptors